Pulmonary embolism (PE) is a cardiovascular disease. It directly impacts the heart and blood vessels, and it falls under the clinical guidelines managed by the American Heart Association and the American College of Cardiology. Their joint 2026 guideline for managing acute PE in adults is explicitly published as part of their mission to “improve cardiovascular health.” While PE originates as a blood clot problem, its danger and its classification come from what it does to the heart.
Why PE Counts as Cardiovascular
Cardiovascular disease is an umbrella term covering any condition that affects the heart or blood vessels. That includes heart attacks, strokes, heart failure, arrhythmias, and vascular diseases. Pulmonary embolism fits squarely in this category because a blood clot lodges in the pulmonary arteries, the vessels that carry blood from the heart to the lungs. This obstruction doesn’t just block blood flow to lung tissue. It forces the right side of the heart to pump against dramatically increased resistance, which can lead to right heart failure and, in severe cases, cardiovascular collapse.
The right ventricle is built for low-pressure work. Unlike the muscular left ventricle, which pushes blood to the entire body, the right side is thin-walled and adapted to a low-resistance circuit. When a clot suddenly blocks a significant portion of the pulmonary arteries, the pressure the right ventricle has to overcome spikes. It can dilate, weaken, and fail rapidly. This is why large pulmonary embolisms are immediately life-threatening: the core problem is acute heart failure, not lung damage.
Where PE Sits Within Cardiovascular Disease
PE belongs to a subcategory called venous thromboembolism (VTE), which also includes deep vein thrombosis (DVT), the blood clots that typically form in the legs before traveling to the lungs. VTE has traditionally been studied somewhat separately from arterial cardiovascular diseases like heart attack and stroke, which involve blockages in arteries feeding the heart or brain. This separation can make it seem like PE and heart disease are unrelated, but the distinction is really about where the clot forms and travels, not about whether the cardiovascular system is involved.
Research published in the New England Journal of Medicine found a direct link between arterial disease and venous clotting. Patients with spontaneous venous thrombosis were roughly twice as likely to have signs of atherosclerosis (plaque buildup in the arteries) compared to control subjects. Nearly half of those with spontaneous clots, 47%, had at least one detectable plaque in their carotid arteries, versus 32% of healthy controls. The two conditions may share underlying mechanisms: atherosclerosis activates both platelets and the blood’s clotting system, increasing the likelihood of clots forming in veins as well as arteries.
Shared Risk Factors With Heart Disease
PE and traditional cardiovascular diseases like heart attack share several major risk factors. These include older age, obesity (higher BMI and waist-to-hip ratio), smoking, diabetes, and physical inactivity. Large studies have compared the risk profiles for fatal coronary heart disease and fatal VTE side by side and found significant overlap in the metabolic and lifestyle factors that drive both conditions. This isn’t a coincidence. The clotting system, inflammation, and blood vessel health are interconnected, so conditions that damage arteries also tend to make the venous system more prone to clots.
That said, PE also has risk factors that are less common in typical heart disease: recent surgery, prolonged immobilization, certain cancers, pregnancy, and inherited clotting disorders. This is part of why VTE has historically been treated as its own clinical specialty, even though it clearly falls under the cardiovascular umbrella.
How PE Is Diagnosed
Doctors assess PE risk using clinical scoring systems like the Wells Score and the revised Geneva Score. These assign points based on factors like a racing heart rate (above 100 beats per minute), recent surgery or immobilization, active cancer, signs of a leg clot, and whether PE is more likely than other explanations for the symptoms. A low score can sometimes rule out PE without imaging, especially when combined with a blood test called D-dimer that detects clot breakdown products.
When the probability is higher or the D-dimer is elevated, the primary imaging tool is CT pulmonary angiography (CTPA), a specialized CT scan that visualizes the blood vessels in the lungs with contrast dye. This replaced older lung ventilation-perfusion scans as the standard in the U.S. by 2001, though those scans still have a role for patients who can’t receive contrast dye due to kidney problems or severe allergies.
How Dangerous PE Is
PE carries a significant mortality risk, particularly in older adults. In one study, the 30-day mortality rate among patients with confirmed PE was 14.2%, and the 90-day rate reached 20.8%. For patients 80 and older, 30-day mortality was nearly 19%, and 90-day mortality climbed to almost 30%. These numbers make PE one of the more dangerous acute cardiovascular events, comparable in urgency to a heart attack.
Severity ranges widely. Small clots in peripheral branches of the pulmonary arteries may cause chest pain and shortness of breath but resolve with blood thinners alone. Massive PE, where clots block the main pulmonary arteries and cause the heart to fail, requires emergency intervention. Treatment in these cases can involve clot-dissolving medications or procedures to physically remove the clot, approaches borrowed directly from the cardiovascular playbook used for heart attacks and strokes.
Long-Term Cardiovascular Effects
For most people who survive a PE, the clot dissolves over weeks to months with blood-thinning treatment, and the heart recovers. But a small percentage develop a chronic condition where organized clot material permanently narrows the pulmonary arteries, leading to persistently high blood pressure in the lungs. This is called chronic thromboembolic pulmonary hypertension (CTEPH), and it’s a progressive cardiovascular disease in its own right.
A study in the New England Journal of Medicine tracked PE survivors and found that the cumulative incidence of CTEPH was about 1% at six months, 3.1% at one year, and 3.8% at two years. After the two-year mark, no new cases developed among the remaining patients who were followed. While 3.8% may sound small, it represents a meaningful number of people left with a serious, lifelong cardiovascular condition. CTEPH causes worsening shortness of breath, exercise intolerance, and right heart strain, essentially the same mechanism as acute PE but playing out slowly over months and years instead of minutes.
The fact that PE can cause both acute heart failure and chronic pulmonary hypertension reinforces its place as a cardiovascular disease. Its management is led by cardiologists, vascular medicine specialists, and interventional radiologists, and its clinical guidelines are published by the same organizations that govern heart attack and stroke care.